PRESENTATIONS

  • Maximizing Your Value Proposition to Garner Needed Financial Support, National Council on Aging Age+Action 2022 Virtual Conference, June 21, 2023 (upcoming).

  • Aligning Falls, Frailty and Fracture Prevention Programs to Maximize Patient Outcomes, National Council on Aging Age+Action 2022 Virtual Conference, June 6, 2022.

  • Value of Post-Fracture Care Programs. Amgen Bone Expert Forum, Cartagena, Colombia, August 17, 2019.

  • Focus on Identification, Investigation and Initiation: The Three Critical I’s in Post-Fracture Care Execution. Amgen Osteoporosis Educational Summit, Barcelona, Spain, October 20, 2018. 

  • Insights from Secondary Fracture Prevention Programs: US Private Setting. American Society for Bone and Mineral Research Fracture Prevention Stakeholder Summit, Crystal City, VA, July 19, 2017.

  • Clinical Transformation to Address Care Gaps and Improve Quality: Reflections on a Unique Platform. Health Datapalooza, Washington, DC, June 1, 2015.

  • Breaking Through: Closing the Care Gap in Secondary Fracture Prevention. American Society for Bone and Mineral Research Annual Meeting, Houston, TX, September 13, 2014.

  • What Makes a Good Fracture Liaison Service Program? Fragility Fracture Network Global Congress, Madrid, Spain, September 5, 2014.

  • National Bone Health Alliance: Multipronged Efforts to Foster the Fracture Liaison Service Model of Care in the United States. International Osteoporosis Foundation Congress, Bordeaux, France, March 22, 2012. 

  • NBHA Secondary Fracture Prevention Initiative: Proposed Implementation of a Fracture Liaison Service in the Medicare System and Beyond. Fracture Prevention Best Practices Summit, Washington, DC, November 11, 2011. 

  • National Bone Health Alliance: Initiatives Under Development. Federal Working Group on Bone Disease, National Institutes of Health, Bethesda, MD, November 1, 2011. 

  • Lessons Learned from Model Programs: The Biomarkers Consortium and the Alzheimer’s Disease Neuroimaging Initiative. Scaling Senior Independent Living Research Workshop, Bethesda, MD, December 7, 2010. 

  • Academic/Industry Issues and Barriers for Diagnostic Development: Experiences of The Biomarkers Consortium. National Institutes of Health Clinical and Translational Science Award Forum, Bethesda, MD, February 18, 2010. 

  • Keynote Speaker, Discovering Quality Biomarkers and Accelerating Translation to Clinical Practice. American Association of Clinical Chemistry/National Cancer Institute/National Heart Lung and Blood Institute Biomarkers Workshop, Bethesda, MD, November 5, 2009. 

  • Facilitating the Development and Qualification of Biomarkers Through a Novel Public‐Private Partnership: The Biomarkers Consortium. ADAPT Short Course on Biomarker Qualification/Development, Washington, DC, September 22, 2009. 

  • ISPY‐2: An Adaptive Breast Cancer Trial in the Neoadjuvant Setting. Avon Foundation Scientific Advisory Board, New York, NY, September 15, 2009. 

  • Driving Innovation to Enhance the Clinical Trial Process and Accelerate Drug Development. Association of Clinical Research Organizations Clinical Outsourcing Leadership Summit, Arlington, VA, November 13, 2008.

  • Facilitating the Development and Qualification of Biomarkers in Alzheimer’s Disease Through Novel Partnerships. CBI Second Annual Alzheimer’s Drug Development Summit, Washington, DC, November 7, 2008.

  • Involvement of Patient/Advocacy Groups in Foundation for National Institutes of Health Partnerships. Institute of Medicine Forum on Neuroscience and Nervous System Disorders, Washington, DC, October 24, 2007.

PUBLICATIONS

  • Akesson K, Ganda K, Deignan C, Volpert A, Brooks K, Lee DB, Singer AJ (Poster). Post-Fracture Care Programs: A Literature Assessment of Where Secondary Fracture Prevention is Today. American Society for Bone and Mineral Research Annual Meeting, Orlando, FL, September 22, 2019.

  • Greenspan SL, Singer A, Vujevich K, Marchand B, Thompson DA, Hsu Y-J, Vaidya D, Stern LS, Zeldow D, Lee DB, Karp S, Recker R. Implementing a fracture liaison service open model of care utilizing a cloud-based too. Osteoporosis International 2018; 29(4): 953-960. 

  • Holzmueller CG, Karp S, Zeldow D, Lee DB, Thompson DA. Development of a Cloud-Based Application for the Fracture Liaison Service Model of Care. Osteoporosis International 2016; 27(2): 1-8.

  • Lee DB, Adler RA, Gagel RF. Treatment of Osteoporosis is not Futile. British Medical Journal 2015 (July), 351: 3274. (Comment on “Overdiagnosis of Bone Fragility in the Quest to Prevent Hip Fracture. British Medical Journal, 2015).

  • Mitchell PJ and Lee DB. Systematic Approaches to Fragility Fracture Prevention. Osteologie 2014; 23:39-44.

  • Top 15 Poster Presentation, National Bone Health Alliance: An Instrumental Force in Improving Bone Health Through Partnership. Fragility Fracture Network Global Congress, Madrid, Spain, September 4, 2014.

  • Lee DB, Lowden MR, Patmintra V, Stevenson K. National Bone Health Alliance: An innovative public-private partnership improving America’s bone health. Current Osteoporosis Reports 2013; 11(4): 348-53.

  • Lee DB (quoted expert), Winter Falls, Bone Fractures May Point to Osteoporosis. USA Today, January 8, 2013. 

  • Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S. National Bone Health Alliance Bone Turnover Marker Project: Current Practices and the Need for U.S. Harmonization, Standardization and Common Reference Ranges. Osteoporosis International 2012, 23(10): 2425‐2433. 

  • Wholley D, Lee DB (Book Chapter). The Biomarkers Consortium: Facilitating the Development and Qualification of Novel Biomarkers through a Precompetitive Public‐Private Partnership. Translational Medicine and Drug Discovery (Editors: Littman BH, Krisha R), Cambridge University Press, March 2011. 

  • Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O’Connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube‐Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, Degennaro LJ, Sigal E, Barker A, Woodcock J. Flurodeoxyglucose‐Positron Emission Tomography (FDG‐PET) Lymphoma Project Invitational Workshop. Academic Radiology (March 2007): 14(3), 330‐339.